Abstract
Objective: The adaptive growth of blood vessels is important to prevent tissue loss following arterial occlusion. Extravasation of monocytes is essential for this process. The peptidase CD26 targets SDF-1 alpha, a chemokine regulating monocyte trafficking. We hypothesized that blocking SDF-1 alpha inactivation, using a commercially available CD26 inhibitor, accelerates perfusion recovery without detrimental side effects on plaque stability. Methods and Results: Atherosclerosis prone ApoE-/- mice underwent femoral artery ligation and received a CD26 inhibitor or placebo. CD26 inhibition increased short term (7 days) perfusion recovery after both single and daily doses compared to placebo, 36%±2 (p=0.017) and 39%±2 (p=0.008) vs. 29%±3 respectively. Long term (56 days) perfusion recovery increased after daily treatment compared to placebo 83%±3 vs. 60%±2, (p<0.001). CD26 inhibition did not result in increased atherosclerotic plaque instability or inflammatory cell infiltration. CD26 inhibition increased macrophage number around growing collaterals, SDF-1 alpha plasma levels and monocyte expression of the activation marker CD11b and the SDF-1 alpha receptor CXCR-4. Conclusions: CD26 inhibition enhanced perfusion recovery following arterial occlusion via attenuated SDF-1 alpha inactivation and increased monocyte activation. There was no observable aggravation of atherosclerosis and CD26 inhibition could therefore offer a novel approach for therapeutic arteriogenesis in patients.
Keywords: CD26, collateral circulation, leukocytes, perfusion recovery, SDF-1 alpha, monocyte activation
Current Vascular Pharmacology
Title:CD26 Inhibition Enhances Perfusion Recovery in ApoE-/-Mice
Volume: 11 Issue: 1
Author(s): Rene T. Haverslag, Daphne de Groot, Sebastian Grundmann, Benjamin Meder, Marie-Jose Goumans, Gerard Pasterkamp, Imo E. Hoefer and Dominique P.V. de Kleijn
Affiliation:
Keywords: CD26, collateral circulation, leukocytes, perfusion recovery, SDF-1 alpha, monocyte activation
Abstract: Objective: The adaptive growth of blood vessels is important to prevent tissue loss following arterial occlusion. Extravasation of monocytes is essential for this process. The peptidase CD26 targets SDF-1 alpha, a chemokine regulating monocyte trafficking. We hypothesized that blocking SDF-1 alpha inactivation, using a commercially available CD26 inhibitor, accelerates perfusion recovery without detrimental side effects on plaque stability. Methods and Results: Atherosclerosis prone ApoE-/- mice underwent femoral artery ligation and received a CD26 inhibitor or placebo. CD26 inhibition increased short term (7 days) perfusion recovery after both single and daily doses compared to placebo, 36%±2 (p=0.017) and 39%±2 (p=0.008) vs. 29%±3 respectively. Long term (56 days) perfusion recovery increased after daily treatment compared to placebo 83%±3 vs. 60%±2, (p<0.001). CD26 inhibition did not result in increased atherosclerotic plaque instability or inflammatory cell infiltration. CD26 inhibition increased macrophage number around growing collaterals, SDF-1 alpha plasma levels and monocyte expression of the activation marker CD11b and the SDF-1 alpha receptor CXCR-4. Conclusions: CD26 inhibition enhanced perfusion recovery following arterial occlusion via attenuated SDF-1 alpha inactivation and increased monocyte activation. There was no observable aggravation of atherosclerosis and CD26 inhibition could therefore offer a novel approach for therapeutic arteriogenesis in patients.
Export Options
About this article
Cite this article as:
T. Haverslag Rene, de Groot Daphne, Grundmann Sebastian, Meder Benjamin, Goumans Marie-Jose, Pasterkamp Gerard, E. Hoefer Imo and P.V. de Kleijn Dominique, CD26 Inhibition Enhances Perfusion Recovery in ApoE-/-Mice, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010021
DOI https://dx.doi.org/10.2174/1570161111309010021 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Activity of Nitric Oxide-releasing Derivatives of Ferulic Acid as Potential Agents for the Treatment of Chronic Kidney Diseases
Medicinal Chemistry From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Non-Insulin Dependent Diabetes Mellitus: Present Therapies and New Drug Targets&#
Mini-Reviews in Medicinal Chemistry The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of Prevention
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Aldose Reductase Inhibitory Potential of Several Thiazolyl-thiazolidine- 2,4-Diones
Letters in Drug Design & Discovery Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research Food as a Bariatric Drug
Current Pharmaceutical Design Nitric Oxide Related Therapeutic Phenomenon: A Challenging Task
Current Pharmaceutical Design Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry The Emerging role of Branch Chain Amino Acids in the Prediction of Diabetes: A Brief Review
Current Diabetes Reviews The Influence of Diabetes Mellitus on Rotator Cuff Repair: A Systematic Review and Meta-Analysis
Combinatorial Chemistry & High Throughput Screening A Review Study on Prakriti (Body Constitution) Specific Herbal Tea in Diabetes Mellitus
Current Traditional Medicine Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clopidogrel in Secondary Ischemic Stroke Prevention
Recent Patents on Cardiovascular Drug Discovery Oxidative Stress in Essential Hypertension
Current Pharmaceutical Design